All In Biotech

Drug Trial Radar · NCT02419001

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

A Phase 1b/2a, Randomized, Multi-center, Open-label, Fixed-sequence Study to Evaluate the Effect of Oral SYN-004 on the Pharmacokinetics of Intravenous Ceftriaxone in Healthy Adult Subjects With a Functioning Ileostomy

Last checked: Nov 19, 2026Latest source record: Nov 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

11

Actual

Start

Mar 2015

Primary completion

Sep 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Theriva Biologics, Inc.Industry
Sponsor type
Industry
First posted
Apr 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1b/2a, Randomized, Multi-Center, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Oral SYN-004 on the Pharmacokinetics of Intravenous Ceftriaxone in Healthy Adult Subjects with a Functioning Ileostomy.

Conditions

  • Healthy Volunteers

Interventions

  • Period 1 - Treatment Sequence ABDrug

    Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004

  • Period 1 - Treatment Sequence ACDrug

    Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004

  • Period 2 - Treatment Sequence ABDrug

    Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg

  • Period 2 - Treatment Sequence ACDrug

    Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ceftriaxone PK Maximum Observed Plasma Concentration (Cmax) With (Period 2) and Without (Period 1) SYN-004.Time frame: 2 weeks
  2. Ceftriaxone PK Time to Reach Cmax (Tmax) With (Period 2) and Without (Period 1) SYN-004.Time frame: 2 weeks
  3. Ceftriaxone PK Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUCt) With (Period 2) and Without (Period 1) SYN-004.Time frame: 2 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Columbus, Ohio

  • Site not named

    Montreal, Canada

  • Site not named

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.